Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02490787 · ClinicalTrials.gov registry record · Phase 1

Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects

A Phase 1 study of Haemophilia A and Congenital Bleeding Disorder, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
20
Study locations

NCT02490787 is a Phase 1 study of Haemophilia A and Congenital Bleeding Disorder that has completed, run by Novo Nordisk A/S. The registered enrollment target is 24 participants, below the 222-participant average among 8 other Haemophilia A trials with a reported enrollment target (89% lower). The trial reports 20 study locations across 11 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02490787, a Phase 1 study of Haemophilia A and Congenital Bleeding Disorder, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
20
Study locations

Study Summary

This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.

Conditions Studied

Haemophilia A Congenital Bleeding Disorder

Interventions

  • DRUG placebo
  • DRUG Concizumab

Study Locations (20)

Other

  • Novo Nordisk Investigational Site - Vienna
  • Novo Nordisk Investigational Site - Zagreb
  • Novo Nordisk Investigational Site - Bron
  • Novo Nordisk Investigational Site - Nantes
  • Novo Nordisk Investigational Site - Rennes
  • Novo Nordisk Investigational Site - Berlin
  • Novo Nordisk Investigational Site - Duisburg
  • Novo Nordisk Investigational Site - Homburg
  • Novo Nordisk Investigational Site - Tel Litwinsky
  • Novo Nordisk Investigational Site - Kuala Lumpur

California

  • Novo Nordisk Investigational Site - Torrance

Indiana

  • Novo Nordisk Investigational Site - Indianapolis

Iowa

  • Novo Nordisk Investigational Site - Iowa City

Maryland

  • Novo Nordisk Investigational Site - Baltimore

New York

  • Novo Nordisk Investigational Site - New York

Oregon

  • Novo Nordisk Investigational Site - Portland

Texas

  • Novo Nordisk Investigational Site - Houston

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2015-09-10
Est. Completion 2016-10-14
Phase Phase 1

Sponsor

Novo Nordisk A/S

431 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02490787

The ClinicalTrials.gov registry entry for NCT02490787 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 222-participant average among 8 other Haemophilia A trials with a reported enrollment target (89% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Haemophilia A appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.

NCT02490787 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, California, Indiana.

Frequently Asked Questions

What is clinical trial NCT02490787 about?

NCT02490787 is a clinical study titled "Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of Concizumab Administered Subcutaneously to Haemophilia A Subjects". This trial is conducted globally. The aim of this trial is to investigate safety, pharmacokinetics (the exposure of the trial drug in the body) and pharmacodynamics (the effect of the investigated drug on the body) of concizumab administered subcutaneously to haemophilia A subjects.

What is the current status of trial NCT02490787?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-09-10. Estimated completion is 2016-10-14.

What conditions does trial NCT02490787 study?

This clinical trial studies the following conditions: Haemophilia A, Congenital Bleeding Disorder.

What interventions are being tested in trial NCT02490787?

The interventions under investigation include: placebo (DRUG), Concizumab (DRUG).

Who is sponsoring clinical trial NCT02490787?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02490787 being conducted?

This trial has 20 study locations across California, Indiana, Iowa, Maryland, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Haemophilia A

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Haemophilia A

All registered trials for this condition

Congenital Bleeding Disorder

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.